Rosen Law Firm Investigates Simulations Plus for Alleged Misleading Information Impacting Investors

Rosen Law Firm Investigates Simulations Plus Amid Allegations of Misleading Information

In a significant development for Simulations Plus, Inc., the Rosen Law Firm has launched an investigation into potential securities claims on behalf of the company’s shareholders. The inquiry arises from allegations that misleading business information may have impacted investors' decisions regarding their holdings in the software and simulation company. This investigation comes on the heels of a report published by Benzinga on July 15, 2025, which indicated a decline in demand and a less optimistic outlook for Simulations Plus. The report highlighted that while the company achieved sales of $20.4 million in the third quarter of 2025—marking a 10% increase compared to the previous year—it fell short of the consensus estimate of $20.9 million, which has raised serious investor concerns.

The timing of the Benzinga article coincides with a notable drop in the company’s stock price, which fell by 25.75% in response to the reported financial performance and outlook. Preliminary sales figures released earlier in June had already pointed to a decline from expectations, further exacerbating investor anxiety. As a result, shareholders who believe they have suffered losses due to these developments may be eligible for compensation through a contingency fee arrangement being prepared by the Rosen Law Firm. This legal action aims to recover losses incurred by those who purchased Simulations Plus securities during the relevant period.

The Rosen Law Firm's reputation as a leading advocate for investor rights is bolstered by its successful track record in securities class actions. With a history of achieving significant settlements—such as recovering over $438 million for investors in 2019 and being recognized for the largest class action settlement against a Chinese company at the time—the firm emphasizes the importance of experienced legal counsel in navigating these complex matters. Shareholders interested in joining the class action can find more information on the firm’s website or through direct contact, as the Rosen Law Firm continues to raise awareness and provide updates on its social media channels.

In addition to the ongoing investigation, the broader implications of the allegations could cast a shadow over Simulations Plus’ reputation in the pharmaceutical and biotechnology industries. As a provider of simulation and modeling software, the company plays a vital role in drug development and regulatory compliance. Maintaining trust and transparency with investors is crucial for Simulations Plus to sustain its position as an industry leader, especially in a sector where precision and reliability are paramount.

As developments unfold, the investigation by the Rosen Law Firm serves as a reminder of the potential consequences of corporate communications and investor relations in the fast-paced world of technology and pharmaceuticals. Stakeholders will be keenly observing the firm’s actions and the company’s response to these allegations, as the outcome may have lasting effects on Simulations Plus' operational integrity and market standing.